ストックスクリーナーアプリを入手
14.47
0.28%
-0.04
前日終値:
$14.43
開ける：
$14.49
24時間の取引高:
848.98K
Relative Volume:
0.65
時価総額：
$2.33B
収益：
$340.81M
当期純損益:
$-419.65M
株価収益率:
-5.0772
EPS:
-2.85
ネットキャッシュフロー:
$-402.10M
1週間 パフォーマンス:
-12.47%
1か月 パフォーマンス:
+11.90%
6か月 パフォーマンス:
-54.10%
1年 パフォーマンス:
-22.92%
1日の値動き範囲:
$14.33
$15.31
1週間の範囲:
$13.36
$16.42
52週間の値動き範囲:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
14.43 | 2.33B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.64 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
532.60 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
550.22 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.16 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.51 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - MSN
Hunter Syndrome Treatment Market Expands with Enzyme - openPR.com
Denali Therapeutics shares fall after price target cut to $32 - Investing.com
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance
Denali Therapeutics Advances Pipeline Amid Financial Loss - TipRanks
Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwright & Co. | DNLI Stock News - GuruFocus
Denali Therapeutics (DNLI) Price Target Revised Amid Strategic Developments | DNLI Stock News - GuruFocus
Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright - TipRanks
Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome - GlobeNewswire
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Biogen (BIIB) Completes Enrollment for Parkinson's Treatment Stu - GuruFocus
First Week of December 19th Options Trading For Denali Therapeutics (DNLI) - Nasdaq
(DNLI) Technical Data - news.stocktradersdaily.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com
Denali Announces Rolling Regulatory Submission of Tividenofusp Alfa for Hunter Syndrome - Neurology live
Denali Therapeutics stock hits 52-week low at $12.05 - Investing.com Australia
Denali Therapeutics stock hits 52-week low at $12.05 By Investing.com - Investing.com Canada
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Zacks Investment Research
Denali Therapeutics set to advance groundbreaking treatments for neurological diseases - MSN
Denali Therapeutics advances Hunter syndrome treatment BLA By Investing.com - Investing.com South Africa
What Happened To Denali Therapeutics Stock Wednesday? - Benzinga
Sector Update: Health Care Stocks Advance in Late Afternoon Trading - TradingView
Sector Update: Health Care - MarketScreener
Denali Therapeutics begins marketing application for genetic disorder drug, shares rise - TradingView
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier - BioSpace
Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up - MarketScreener
How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals
Denali Therapeutics Announces Initiation of BLA Filing for - GlobeNewswire
Denali Therapeutics advances Hunter syndrome treatment BLA - Investing.com
Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome - MarketScreener
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewswire
Breakthrough: Denali's Hunter Syndrome Drug Enters Final FDA Approval Stage - Stock Titan
Trend Tracker for (DNLI) - news.stocktradersdaily.com
Denali Therapeutics stock hits 52-week low at $13.95 By Investing.com - Investing.com South Africa
Denali Therapeutics stock hits 52-week low at $13.95 - Investing.com Australia
Exponential Growth Expected for Blood Brain Barrier Market With - openPR.com
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha
Why You Shouldn't Bet Against Denali (DNLI) Stock - Barchart
(DNLI) On The My Stocks Page - news.stocktradersdaily.com
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
Denali halts extension of DNL343 arm in HEALEY ALS trial - ALS News Today
Denali Therapeutics (NASDAQ:DNLI) Given New $28.00 Price Target at Bank of America - Defense World
Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst Downgrade - Defense World
Why Denali Therapeutics Shares Are Tumbling - TipRanks
Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Denali Therapeutics (NASDAQ:DNLI) Earns Overweight Rating from Analysts at Morgan Stanley - Defense World
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
Denali Therapeutics Inc (DNLI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ho Carole | Chief Medical Officer |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
175,673 |
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '25 |
Sale |
20.22 |
12,255 |
247,796 |
247,215 |
| Schuth Alexander O. | COFO and Secretary |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
244,308 |
| Watts Ryan J. | President and CEO |
Jan 06 '25 |
Sale |
20.22 |
29,266 |
591,759 |
260,721 |
| Watts Ryan J. | President and CEO |
Jan 07 '25 |
Sale |
20.81 |
7,650 |
159,196 |
253,071 |
| Krognes Steve E. | Director |
Jan 07 '25 |
Sale |
20.81 |
3,339 |
69,485 |
25,757 |
2.11%
0.83%
大文字化:
|
ボリューム (24 時間):